After many years, the last year’s organization of the traditional international conference Free Market Roadshow, which has been organized by INESS in cooperation with AEC was cancelled due to the pandemic. This year, it was brought back – into the online space – and dedicated to the topic which has been perhaps the most pertinent for the last year and for many years to come: Pandemic Lessons.
It is the summer of the second year of the COVID-19 panemic, and the European Union has generously opened its coffers to spend on post-pandemic recovery. Various governments of the EU are scrambling to put forward their best ideas to be funded by the new support scheme.
The European Commission has launched an initiative on the evaluation and revision of the general pharmaceutical legislation with an overall aim to ensure a future-proof and crisis-resistant regulatory system.
With the below 101 groups from 47 countries, we celebrate World Intellectual Property Day with WIPO and the creativity, inventiveness, and entrepreneurial spirit protected by intellectual property rights around the world.
The northernmost Baltic state is in the overall comparison quite successful in fighting the COVID-19-pandemics. To this success contributed among other things the central electronic health system.
As urbanization is continuing in a rapid speed it will also drive the further demand for energy resources. World energy consumption is expected to increase 39% by 2050. Knowing all that and thinking about our energy sector, what could be three suggestions to make?
Visio institut is pleased to join the Property Rights Alliance in the celebration of the World IP Day with the launch of an open letter addressed to the World Intellectual Property Organization’s Director General Dr Francis Gurry.
Global trade growth has been in a slowdown for a decade. Contributing to the trend is a recent rise in protectionist policies, particularly in the United States. On top of it, Brexit, no matter in what form it takes, is projected to decrease trade volumes.
Slovak public has recently experienced number of front-page stories about patients, who were refused payment for innovative highly expensive drugs by health insurance companies. Stories, which attracted a lot of emotions and stirred the public and which are vanguard of much bigger future troubles in public healthcare.